IP Library Granted Patent US 9,822,116
Granted Patent B2
US 9,822,116 · App. 15/012,422 · Granted Nov 21, 2017

Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds

Inventors: George G. Wu (Basking Ridge, NJ); Gerald Werne (Ketsch, DE); Xiaoyong Fu (Edison, NJ); Robert K. Orr (Cranford, NJ); Frank Xing Chen (Plainsboro, NJ); Jian Cui (Edison, NJ); Victoria M. Sprague (Bridgewater, NJ); Fucheng Zhang (Edison, NJ); Ji Xie (Edison, NJ); Liansheng Zeng (Union, NJ); Louis Peter Castellanos (Union City, NJ); Yuyin Chen (Garwood, NJ); Marc Poirier (Stewartsville, NJ); Ingrid Mergelsberg (Mahwah, NJ)
Assignee: OPKO Health, Inc.
C07D471/10C07C217/46C07C217/48C07D207/26C07D207/267C07D207/28C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,116
App. No.
15/012,422
Granted
Nov 21, 2017
Kind
B2
Abstract

This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations, intermediates useful in said process, and processes for preparing said intermediates; also disclosed is a process for removal of metals from N-heterocyclic carbine metal complexes.

Claims (36)

1. A process for preparing compound VIII:

the process comprising treating compound I:

with hydrochloric acid;

wherein compound I is prepared from compound VII or VIIb:

wherein “salt 3” represents at least one proton bonded to a base functional group in the compound VII.

2. The process of claim 1 , wherein the compound I is prepared by treating compound VII:

with a reagent suitable to reduce compound VII,

wherein “salt 3” represents at least one proton bonded to a base functional group in the compound VII.

3. The process of claim 1 , wherein the compound I is prepared by treating compound VIIb

with a reagent suitable to reduce compound VIIb.

4. The process of claim 3 , wherein the compound VIIb is prepared by treating compound VII:

with a hydroxide base of Formula M-OH,

wherein

“salt 3” represents at least one proton bonded to a base functional group in the compound VII; and

“M” is an alkaline metal or alkali earth metal to provide the compound VIIb.

5. The process of claim 2 or claim 4 , wherein the compound VII is prepared by treating compound VIa:

with a ring-closing metathesis catalyst,

wherein “salt 2” represents at least one proton bonded to a base functional group in the compound VIa.

6. The process of claim 5 , wherein the compound VIa is prepared by treating compound VI:

with an acid.

7. The process of claim 6 , wherein the compound VI is prepared by treating compound V:

with a reagent suitable to reduce compound V.

8. The process of claim 7 , wherein compound V is prepared by combining compounds III and IV to form a mixture:

wherein the mixture is heated.

9. The process of claim 1 , wherein the compound VIII is recrystallized to provide compound Ia:

10. The process of claim 2 , wherein the reagent suitable to reduce compound VII is a source of hydrogen.

11. The process of claim 10 , wherein, in addition to the source of hydrogen, the compound VII is treated with a catalyst selected from: palladium on carbon, palladium oxide, platinum on carbon, Wilkinson's catalyst (chlorotris(triphenylphosphine)rhodium(I)), and any combination thereof.

12. The process of claim 3 , wherein the reagent suitable to reduce compound VIIb is a source of hydrogen.

13. The process of claim 12 , wherein, in addition to the source of hydrogen, the compound VIIb is treated with a catalyst selected from: palladium on carbon, palladium oxide, platinum on carbon, Wilkinson's catalyst (chlorotris(triphenylphosphine)rhodium(I)), and any combination thereof.

14. The process of claim 4 , wherein the hydroxide base is NaOH.

15. The process of claim 2 , wherein salt 3 is an HCl salt.

16. The process of claim 3 , wherein salt 3 is an HCl salt.

17. The process of claim 5 , wherein salt 2 is the same or different as salt 3.

18. The process of claim 5 , wherein salt 2 is a TsOH salt.

19. The process of claim 6 , wherein the acid is selected from: p-toluene sulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, HCI, HBr, and sulfuric acid.

20. The process of claim 7 , wherein the reagent suitable to reduce compound V is selected from: sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride.

Assignments (5)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS AT R/F 41939/0487, 46591/0544 AND 53940/0001 Recorded Apr 15, 2026
From: MIDCAP FINANCIAL TRUST
To: TERSERA THERAPEUTICS LLC,
Reel/Frame 075420/0453 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2023
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: TERSERA THERAPEUTICS LLC
Reel/Frame 063253/0942 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Jul 19, 2018
From: TERSERA THERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046591/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: WU, GEORGE G.; WERNE, GERALD; FU, XIAOYONG; ORR, ROBERT K.; CHEN, FRANK XING; CUI, JIAN; SPRAGUE, VICTORIA M.; ZHANG, FUCHENG; XIE, JI; ZENG, LIANSHENG; CASTELLANOS, LOUIS PETER; CHEN, YUYIN; POIRIER, MARC; MERGELSBERG, INGRID
To: SCHERING CORPORATION
Reel/Frame 040063/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: SCHERING CORPORATION
To: OPKO HEALTH, INC.
Reel/Frame 039762/0747 →
Continuity (4)
Division 14043210 · Oct 1, 2013
Continuation 13062454
Provisional Application 61094474 · Sep 5, 2008
Related Publication 20160145256A1 · May 26, 2016